Abstract S-palmitoylation is an important post-translational modification that affects the translocation and the activity of target proteins in a variety of cell types including cardiomyocytes. Since endothelial nitric oxide synthase (eNOS) is known to be palmitoylated and the activity of eNOS is essential in fatty aciddependent β-oxidation in muscle, we aimed to test whether palmitoylation of eNOS is involved in palmitic acid (PA) regulation of left ventricular (LV) myocyte contraction from healthy (sham) and hypertensive (HTN) rats. Our results showed that PA, a predominant metabolic substrate for cardiac β-oxidation, significantly increased contraction and oxygen consumption rate (OCR) in LV myocytes from sham. Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) or eNOS gene deletion prevented PA regulation of the myocyte contraction or OCR, indicating the pivotal role of eNOS in mediating the effects of PA in cardiac myocytes. PA increased the palmitoylation of eNOS in LV myocytes and depalmitoylation with 2-bromopalmitate (2BP; 100 μM) abolished the increment. 
Introduction
Fatty acids are the predominant metabolic substrates that play important roles in cardiac metabolism and myocardial function [3, 11] . Palmitic acid (PA; a 16-carbon saturated fatty acid), which is one of the most common saturated fatty acids for myocardial ATP, has been implicated in the regulation of cardiac contraction. However, the mechanism of this regulation is not fully understood. Recent evidence indicates that nitric oxide (NO) that is derived from endothelial NOS (eNOS) may play a critical role in the regulation of energy production and fatty acid utilization by muscle. For example, Le Gouill et al. demonstrated that oxygen consumption in muscle from eNOS gene knockout (eNOS −/− ) mice is impaired compared to that in normal mice [8] . Furthermore, mitochondrial β-oxidation was reduced in eNOS −/− mice [8] .
Since NO is well established to affect myocardial function, including the modulation of contraction, energetics (metabolism), and signaling pathways [5, 12] , eNOS may regulate PAdependent myocyte contraction in the heart. S-palmitoylation is an important post-translational modification that affects the translocation and the activity of target proteins in the cells, and the reversible nature of palmitoylation provides a potential mechanism for protein shuttling between intracellular compartments [9] . eNOS is known to be palmitoylated [10] and it is possible that the activity of eNOS is altered to play a part in fatty acid β-oxidation in cardiac myocyte and regulate myocardial contractility. Recently, we have shown that eNOS protein expression is reduced in angiotensin II (Ang II)-induced hypertensive myocardium [7] . Reduced NO bioavailability is able to impair cardiac metabolism and reduce the capacity of fatty acid oxidation [5, 11] . We hypothesize that PA regulation of myocyte contraction is impaired due to the lack of eNOS palmitoylation in hypertensive heart.
Here, we aimed to identify whether eNOS is palmitoylated by PA in left ventricular (LV) myocytes and how this posttranslational modification affects eNOS activity (eNOS phosphorylation) in healthy heart and in hypertension. Furthermore, we aimed to identify whether eNOS palmitoylation contributes to PA regulation of myocyte contraction and mitochondrial activity in healthy heart and whether this effect is diminished in hypertension.
Materials and methods

Animals
Sprague-Dawley rats (10-12 weeks old, male) were used in the study. Hypertension was induced by infusing Ang II subcutaneously in rats using osmotic minipumps, and they were paired with sham-operated group, as reported before [7] . Briefly, rats (of 8 weeks old, male) were anesthetized with isoflurane (2.5%). An osmotic minipump (Alzet model 2004, DURECT Corporation, San Francisco, CA, USA) containing Ang II (200 μl, 6 mM, infusion rate 125 ng/min/kg) was implanted in the mid-scapular region for 4 weeks. Shamoperated animals underwent the same surgical procedure, except for no pump insertion. Blood pressures were measured every 3 days for 4 weeks by Non-Invasive Blood Pressure System, tail-cuff method (CODA, Torrington, CT, USA). The study protocol was in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996), and also conforms to the Institutional Animal Care and Use Committee (IACUC) in Seoul National University (IACUC approval No.: SNU-101213-1; SNU-160119-4-1).
eNOS knockout mice (21-to 25-week-old males) were provided by Professor Goo Taeg Oh's Laboratory (Ewha Woman's University, Seoul, Korea).
Isolation of left ventricular myocytes
LV myocytes were isolated enzymatically by Langendorff perfusion system as recently described [14] . Briefly, the rats were anesthetized with pentobarbital sodium (30 mg/kg, i.p.) and the hearts were extracted and rapidly mounted onto the Langendorff perfusion system. The isolated heart was perfused with a nominally Ca 2+ -free solution for 10 min (in mM, NaCl 135, KCl 5.4, MgCl 2 3.5, glucose 5, HEPES 5, Na 2 HPO 4 0.4, taurine 20; pH titrated to 7.40 using NaOH), followed by a further 8 min with the same solution with enzymes added (collagenase type 2, 1 mg/ml, Worthington Biochemical Corporation, Lakewood, NJ, USA; protease, 0.1 mg/ml, bovine serum albumin (BSA) 1.67 mg/ml; Ca 2+ 0.05 mM). The LV-free wall was isolated and placed in a separate flask containing fresh collagenase-only solution for 8 min (oxygenated and maintained at 37°C). Myocytes were harvested following a further 10-min digestion period, washed, and re-suspended in storage solution (in mM, NaCl 120, KCl 5.4, MgSO 4 5, CaCl 2 0.2, Na-pyruvate 5, glucose 5.5, Taurine 20, HEPES 10, D-mannitol 29; pH titrated to 7.40 using NaOH). The myocyte suspension was stored at room temperature and cells were used within 8 h of isolation.
S-palmitoylation of eNOS
Following Dr Will Fuller's protocol for eNOS palmitoylation (University of Dundee), LV myocytes were diluted with blocking buffer (100 mM HEPES, 1 mM EDTA, 2.5% SDS, 1% MMTS, pH 7.5) to block the free thiol and incubated at 40°C for 4 h. Following acetone precipitation, the pellet was rinsed five times with 70% cold acetone and added in binding buffer (100 mM HEPES, 1.0 mM EDTA, 1% SDS, pH 7.5). When employed, an equal volume of freshly prepared 2 M NH 2 OH (pH adjusted to 7.0 with 2 M NaCl) was added followed by prewashed thiopropyl-Sepharose (SigmaAldrich, Seoul, Korea). Binding reactions were carried out on a rotator at room temperature for 2.5 h. Each of supernatant was saved as the Btotal input.^Resins were washed at least seven times with binding buffer. For immunoblot analysis, elution was performed using 2× Laemmli sample buffer supplemented with 100 mM DTT and heated to 95°C for 5 min. The obtained sample was separated via SDS-PAGE and immunoblotting with eNOS. S-palmitoylation of eNOS was compared in LV myocytes before and after palmitic acid treatment [4] .
Measurement of LV myocyte contraction
Isolated LV myocytes were superfused with normal Tyrode's solution containing (in mM, NaCl 141.4, KCl 4, NaH 2 PO 4 0.33, MgCl 2 1, HEPES 10, glucose 5.5, CaCl 2 1.8, mannitol 14.5; pH titrated to 7.40 using NaOH) in the recording bath mounted on the stage of a high-resolution inverted microscope (Diaphot 200, Nikon, JP). Changes in sarcomere length were measured in LV myocytes by using a video-sarcomere detection system (IonOptix Corporation, Milton, MA, USA). Measurements from at least 10 steady state contractions were averaged for each intervention. All experiments were carried out at 36 ± 1°C and field stimulated at 2 Hz [14] .
Measurement of oxygen consumption rate from LV myocytes
According to the manufacturer's instructions, oxygen consumption rate (OCR) was measured using a fluorescence-based oxygen sensor (NeoFox, Ocean Optics, Dunedin, FL, USA) connected to a phase measurement system (Instech Laboratories, Inc., Plymouth Meeting, Philadelphia, USA). The sensor was calibrated regularly (every week) according to the manufacturer's instructions. Briefly, isolated LV myocytes (density 2 × 10 4 /ml) were suspended in normal Tyrode's solution and was placed in a sealed chamber (300 μl). Record oxygen level in the chamber over 30-min period (37°C) followed by about 5-min recordings with carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP; 20 μM) to evaluate maximum OC of the myocytes in the chamber. Changes in the OCR with PA with and without nNOS inhibitor were calculated over 30-min period in sham and HTN.
Immunoblotting
LV myocytes that were lysed in lysis buffer contained 50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1% Triton X-100, and 5 mM EDTA with protease/phosphatase inhibitor cocktail (Roche Diagnostics, Mannhaim, Germany). Cell lysates were then centrifuged at 14,000g for 30 min at 4°C, and the supernatants were acquired. The protein concentration was determined by the Bradford assay. The protein sampled were mixed with Laemmli sample buffer, resolved by 6 and 10% SDS-PAGE, and transferred to polyvinylidine difluoride membranes in 25 mM Tris, 192 mM glycine, and 20% methanol. Membranes were blocked in 1× TBS containing 1% Tween-20 and 5% bovine serum albumin (blocking solution) for 1 h at room temperature with gentle rocking, and incubated overnight at 4°C with anti-eNOS (BD Transduction Laboratories), eNOS-Ser 1177 (BD Transduction Laboratories, San Francisco, CA, USA), GAPDH (Santa Cruz, Dallas, TX, USA) primary antibodies, followed by relevant secondary antibodies after washing. Blots were developed by ECL Plus Western blotting detection reagents (Amersham Bioscience, Piscataway, NJ, USA). Membranes were stripped using Pierce restore western blot stripping buffer (Thermo Scientific, Waltham, MA, USA) for 30 min, and the relative densities were calculated after normalizing the intensity of each sample band to that of GAPDH.
NO production
NO production was detected indirectly by measuring nitrite content in LV myocytes using NO assay kit (Griess Reagent System, Sigma-Aldrich, Seoul, Korea). Briefly, LV myocytes were homogenized in HEPES buffer solution (in mM, NaCl 141.4, KCl 4, NaH 2 PO 4 0.33, MgCl 2 1, HEPES 10, glucose 5.5, CaCl 2 1.8, mannitol 14.5, mixtures of phosphatase inhibitors and protease inhibitors; pH titrated to 7.40 using NaOH). After assaying the protein content with Bradford protocol, 50 μl of the supernatant of lysates was added to wells and mixed with 50 μl of sulfanilamide solution and incubated for 5-10 min at room temperature in the dark. The same volume of naphthylethylenediamine dihydrochloride (NED; Sigma-Aldrich) solution was added to the wells and incubated for another 5-10 min at room temperature, protected from light. Absorbance of the mixture was measured with a microplate plate reader (at 540 nm, PowerWave ™ XS Microplate Spectrophotometer, BioTek Instruments, USA). Sodium nitrite (Sigma-Aldrich) was used as a standard.
Chemicals
Angiotensin II (Ang II; 6 mM) was injected to the osmotic minipumps. S-methyl-L-thiocitrulline acetate salt (SMTC; 100 nM, Sigma) and Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME; 1 mM, Sigma) were used to target nNOS and NOS activities. Sodium nitroferricyanide (III) dehydrate (SNP; 10 μM, Sigma) was an exogenous NO donor. PA (100 μM, Sigma) was used to stimulate fatty acid oxidation. 2-Bromopalmitic (2BP; 100 μM, Sigma) acid was an inhibitor of S-palmitoylation. Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP; 20 μM, Sigma) was an uncoupling agent-induced maximal oxygen consumption rate. Sodium hydrosulfite or hyposulfite (Na 2 S 2 O 4 ; Sigma-Aldrich) was used in calibration for OCR by minimizing O 2 level in the solution.
Statistics
Data are reported as mean ± SEM. N indicates the number of cells used. For all comparisons, cells were obtained from a minimum of three hearts per treatment group per protocol. Data were analyzed using student's paired and unpaired t test. A value of p < 0.05 was considered to be statistically significant. Data are reported as mean ± SEM.
Results eNOS mediates PA regulation of myocyte contraction
Figure 1a, d shows that PA (100 μM) significantly increased sarcomere shortening in LV myocytes from sham rats (p < 0.0001, control vs. PA in shams, n = 13). However, the positive inotropic effect of PA was absent in the presence of a non-specific inhibitor of NOS, L-NAME (1 mM, 30 min to 1 h) (p = 0.26, control vs. PA in pre-treatment of L-NAME in shams, n = 8; p < 0.001, PA vs. L-NAME + PA in sham, n = 13 and n = 8; Fig. 1b ; Fig. 1c , e). We performed additional experiments to observe whether eNOS affects mitochondrial activity (OCR) in LV myocytes from sham rats with and without eNOS inhibition and from eNOS −/− mice. As shown in Fig. 2a , PA significantly increased OCR in LV myocytes from sham at control but not with L-NAME (p = 0.004, control vs. PA in shams, n = 10 and n = 9; p = 0.4935, L-NAME vs. L-NAME + PA, n = 8 each; p = 0.1951, control vs. L-NAME in sham, n = 10 and n = 8; p = 0.008, PA vs. L-NAME + PA, n = 9 and n = 8). This is in contrast to the inhibition of neuronal NOS (nNOS) with SMTC (100 nM, 30 min to 1 h), where PA failed to affect the OCR (p = 0.0239, SMTC vs. SMTC + PA in shams, n = 8 and n = 10; Fig. 2a ). In line with this result, PA failed to increase myocyte shortening following SMTC pre-treatment (data not shown). In addition, PA did not induce an increase in OCR in LV myocytes from eNOS −/− mice; on the contrary, PA reduced OCR in eNOS −/− (p = 0.0329, control vs. PA in eNOS −/− mice, n = 6 and n = 7; Fig. 2b ). These data indicate that eNOS is essential in mediating PA regulation of myocyte contraction through stimulating mitochondrial activity. Figure 3a shows that PA (100 μM) increased eNOS palmitoylation in LV myocytes from sham rats (p = 0.023, control vs. PA in sham, n = 6; Fig. 3a) . Pre-treatment of LV myocytes with a palmitate analog that is the most commonly used to inhibit palmitoylation in cells, 2BP acid (100 μM, 10-30 min), abolished PA-induced eNOS palmitoylation (p = 0.005, PA vs. PA + 2BP in sham, n = 6).
S-palmitoylation of eNOS and its regulation of eNOS phosphorylation and OCR
Furthermore, we aimed to observe whether the palmitoylation of eNOS affects its activity by regulating eNOS-Ser 1177 . As shown in Fig. 3b , eNOS-Ser 1177 was not affected by PA in LV myocytes from sham. However, 2BP significantly reduced eNOS-Ser 1177 with and without PA (p = 0.235, control vs. PA; p = 0.02677, control vs. 2BP; p = 0.00949, PA vs. PA + 2BP; p = 0.01294, 2BP vs. PA + 2BP in sham, n = 6; Fig. 3b) . Paradoxically, the NO production (nitrite level relative to control), which was reduced by PA (84% of control, p = 0.045, n = 6), significantly increased by 2BP in sham (112%, p = 0.152, control vs. 2BP, n = 6; 139%, p = 0.028, PA vs. PA + 2BP, n = 6). Furthermore, neither SMTC nor L-NAME prevented the effect of 2BP (147%, p = 0.03, SMTC vs. SMTC + PA + 2BP, n = 8; 149%, p = 0.02, L-NAME vs. L-NAME + PA + 2BP, n = 8). Therefore, the effect of 2BP on eNOS-Ser 1177 does not associate with myocyte NO level in sham. To examine whether eNOS palmitoylation affects the function of PA-dependent responses in LV myocytes, both OCR and myocyte contraction were detected with 2BP pre-treatment. As shown in Fig. 3c , pre-treatment LV myocytes with 2BP failed to affect PA potentiation of OCR in sham (p = 0.004, control vs. PA; p < 0.0001, 2BP vs. PA + 2BP; p = 0.0752, PA vs. PA + 2BP; Fig. 3c ). NOS inhibition with L-NAME prevented PA-dependent OCR increase in the presence of 2BP (p < 0.0001, PA + 2BP vs. L-NAME + PA + 2BP; Fig. 3c) .
Furthermore, treatment of LV myocytes with 2BP did not affect myocyte contraction with PA in sham (p < 0.0001, control vs. PA, p = 0.0015, PA vs. PA + 2BP, n = 13; Fig. 4a, d ). Pre-treatment of 2BP did not prevent PA-dependent myocyte contraction (p = 0.005, 2BP vs. 2BP + PA, n = 8; Fig. 4b, e) . Similarly, 2BP did not affect myocyte contraction in the presence of L-NAME; i.e., PA did not increase myocyte contraction in the presence of L-NAME and 2BP (p = 0.406, L-NAME + PA vs. L-NAME + PA + 2BP, n = 8; Fig. 4c, f) . These results exclude the effect of eNOS palmitoylation on eNOS-mediated and PA-induced myocyte contraction in sham.
Palmitoylation of eNOS in PA regulation of LV myocyte contraction and OCR from HTN rats
In HTN, PA did not increase eNOS palmitoylation (p = 0.58, control vs. PA, n = 4; Fig. 5a ). However, 2BP significantly reduced eNOS palmitoylation in the presence and absence of PA (p = 0.04, PA vs. PA + 2BP; Fig. 5a ), suggesting that basal eNOS is palmitoylated and PA does not affect it further. Similar to that in sham, 2BP significantly reduced eNOSSer 1177 in HTN with and without PA (with PA, p = 0.038, PA vs. PA + 2BP; without PA, p = 0.05, control vs. 2BP, n = 3; Fig. 5b ). In addition, the NO production was significantly increased by 2BP in the presence of SMTC and L-NAME (140%, p = 0.02 SMTC vs. SMTC + PA + 2BP, n = 8; 180%, p = 0.01, L-NAME vs. L-NAME + PA + 2BP, n = 8). Unexpectedly, 2BP reduced PA-induced OCR in HTN (p = 0.0177, control and PA, n = 8 and n = 9; p = 0.0198, PA vs. PA + 2BP, n = 9 and n = 10; p = 0.2419, 2BP vs. PA + 2BP, n = 8 and n = 10; Fig. 5c) .
Finally, the effect of PA on myocyte contraction and the involvement of eNOS palmitoylation are examined. As shown in Fig. 6 , PA-dependent positive inotropic effect was absent in HTN (p = 0.3896, control vs. PA, n = 12; Fig. 6a, d ). This effect was unaffected by 2BP (p = 0.069, 2BP vs. PA + 2BP in HTN, n = 5; Fig. 6b, e) . NOS inhibition with L-NAME significantly increased myocyte contraction with PA and 2BP did not affect such an effect (Fig. 6c, f) , indicating the lack of an effect of eNOS and its palmitoylation on myocyte contraction in HTN. These results show clear evidence that eNOS is palmitoylated in LV myocytes from HTN and does not change myocyte contraction with or without PA.
Discussion
In the present study, we showed convincing evidence that a longchain fatty acid, PA, significantly increased LV myocyte contraction from healthy rat heart. This effect was prevented by pharmacological inhibition of eNOS with L-NAME or with eNOS gene deletion (eNOS −/− ). Furthermore, PA increased mitochondrial activity (OCR) in LV myocytes which was prevented by L-NAME or eNOS −/− . In contrast, inhibition of nNOS with SMTC did not affect PA-induced myocyte contraction or mitochondrial activity. These results suggest that the effects of PA on myocyte contraction and mitochondrial activity are mainly mediated by eNOS but not by nNOS. Immunoblotting experiments showed direct evidence that PA increased the palmitoylation of eNOS which was abolished by a potent blocker of palmitoylation, 2BP. Interestingly, depalmitoylation of eNOS with 2BP was associated with a reduction of eNOS phosphorylation at Ser 1177 . However, 2BP, either pre-treatment or post-treatment, did not affect the inotropic effect of PA or PA regulation of mitochondrial activity in LV myocytes, excluding the role of eNOS palmitoylation as the mediating mechanism. In addition, most of residual eNOS was shown to be palmitoylated in LV myocytes from HTN rats. Depalmitoylation of eNOS with 2BP did not affect LV myocyte contraction in the presence and absence of PA, despite its inhibitory effect on eNOS Ser 1177 in HTN. To our knowledge, this is the first study to exam the influence of eNOS and its palmitoylation in the regulation of LV myocyte contraction following supplementation of a favorable metabolic substrate of the myocardium in healthy and hypertensive hearts.
Fatty acids are the predominant metabolic substrates for myocardial ATP and therefore play essential roles in the contractility of the heart. During disease progression, glucose oxidation or glycolysis becomes the predominant sources of energy, whereas both glucose and fatty acid metabolism are downregulated in the failing myocardium [13] . Understanding the mechanisms regulating cardiac contractility with fatty acid-dependent metabolism in healthy and diseased hearts are important in better defining the molecular targets underlying cardiac contraction in physiological and pathological conditions. Here, our results showed that PA increased myocyte contraction and mitochondrial activity (OCR). It is possible that PA exerts these effects through promoting β-oxidation in the mitochondria because our additional studies showed that PA increased ATP production from LV myocytes and both myocyte contraction and ATP level were normalized following the inhibition of carnitine palmitoyltransferase, a key limiting factor of β-oxidation [6] . The effect of PA on myocyte contraction was absent in HTN, indicating functional remodeling of cardiac metabolism in regulating contraction under pressure overload.
On the other hand, PA is also the essential substrate for a post-translational modification, S-palmitoylation. As such, PA may affect myocyte contraction through changing the activities of the mediator proteins. Intriguingly, our results showed that eNOS plays a critical role in mediating PA regulation of myocyte contraction. The palmitoylation of eNOS was significantly increased by PA, which was reversed by pre-treatment of the inhibitor, 2BP. It is well established that the palmitoylation of eNOS is associated with its translocation to plasma membrane (caveolae) and increased its activity in endothelial cells [10] . There are evidences showed the interplays between eNOS palmitoylation and phosphorylation, that is, inhibition of eNOS palmitoylation with another potent inhibitor of palmitoylation, triacsin C, significantly reduced eNOS phosphorylation in cultured endothelial cells [1] . Paradoxically, triacsin C increased NO level in these experiments [1] . Similar to the responses in the report, our results showed that eNOS-Ser 1177 was significantly reduced by 2BP in the presence and absence of PA. Moreover, in line with the results shown in endothelial cells [1] , 2BP increased NO production in LV myocytes before and after PA supplementation. However, neither L-NAME nor SMTC affected the increment of NO, excluding the roles of eNOS or nNOS. Although 2BP is a potent and reliable inhibitor of palmitoylation, it has been shown to exert off-target effects [2] . Therefore, 2BP may regulate NO level in myocyte samples through alternative mechanisms-it is speculative to suggest that 2BP increases cellular NO by preventing cysteine residues of NO-binding proteins. Nevertheless, 2BP did not affect OCR with or without PA supplementation; i.e., PA increased OCR in 2BP pretreated LV myocytes, suggesting that 2BP does not affect the functional regulation of PA on the mitochondria in LV myocytes (despite increased NO level). Accordingly, 2BP was used to exam the effect of de-palmitoylation on PA regulation of myocyte contractility. Similar to its effect on mitochondrial activity, 2BP did not affect myocyte contraction, either pre-treated or post-treated, demonstrating that depalmitoylation process, eNOS depalmitoylation in particular, is not the major mechanism mediating PA regulation of myocyte contraction.
In HTN, cardiac NOSs are remodeled, exhibiting reduced eNOS protein level and greater nNOS protein expression and activity [7] . In our study, the residual eNOS was palmitoylated in HTN, judging from the significant reduction of eNOS palmitoylation by 2BP with and without PA. Palmitoylation of eNOS may have maintained the activity of eNOS since eNOS-Ser 1177 was minimized by 2BP and 2BP reduced PAdependent OCR increment in HTN. However, the significance of this modification remains uncertain. It is possible that reduced eNOS activity underlie the lack of PA-dependent inotropic response on LV myocytes in HTN, regardless of its palmitoylation since 2BP did not affect myocyte contraction in HTN. Inhibition of cardiac NOSs with L-NAME significantly increased myocyte contraction in HTN; similar results were shown with SMTC, suggesting nNOS modulation of myocyte contraction by PA in HTN. Notably, 2BP did not affect myocyte contraction even in the presence of L-NAME, excluding the involvement of eNOS palmitoylation in myocyte contraction by PA in HTN.
Taken together, our observations suggest a role of eNOS in mediating PA regulation of myocyte contraction in healthy rat its post-transcriptional modification in regulating cardiac metabolism and contraction in healthy and diseased heart need further investigation, which may provide novel insights into therapeutic targets to improve myocardial contractile function when necessary.
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